-transparent.png){kind=logo}
Thirty-three evaluable patients who had not received prior chemotherapy were entered on a study of vincristine therapy for advanced or recurrent endometrial carcinoma. Vincristine 1.4 mg/m2 was given weekly as an i.v. bolus for 4 weeks and then every other week. There was one complete response (CR) lasting 5 months. Five patients had partial responses (PR) lasting 3-18 months. The CR+PR rate was 18% (95% confidence interval for CR+PR was 7-36%). Thirteen patients (38%) had stable disease from 2-28 months, and 14 had progressive disease. The major toxicity was neurological, with 11 patients having grade 2 or 3 peripheral neuropathy. Vincristine at this dose and schedule has modest activity, but troublesome toxicity in advanced or recurrent endometrial carcinoma.
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
August 2000,
Gynecologic oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
August 1982,
Cancer treatment reports,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
February 1986,
American journal of clinical oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
January 1979,
Cancer treatment reports,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
June 2003,
Gynecologic oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
December 2002,
Gynecologic oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
January 2010,
Gynecologic oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
February 2002,
Gynecologic oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
February 1990,
American journal of clinical oncology,
G O Broun, and
J A Blessing, and
G L Eddy, and
M D Adelson
June 1984,
American journal of clinical oncology,
